Cargando…
Clinical outcomes and immune phenotypes associated with STK11 co-occurring mutations in non-small cell lung cancer
BACKGROUND: STK11 mutation in non-small cell lung cancer (NSCLC) is associated with worse survival as well as primary resistance to PD-1/PD-L1 targeting immunotherapy. We hypothesize that co-occurring mutations and tumor mutation burden (TMB) may impact response to therapy and prognosis. METHODS: Fo...
Autores principales: | Malhotra, Jyoti, Ryan, Brid, Patel, Malini, Chan, Nancy, Guo, Yanxiang, Aisner, Joseph, Jabbour, Salma K., Pine, Sharon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264081/ https://www.ncbi.nlm.nih.gov/pubmed/35813711 http://dx.doi.org/10.21037/jtd-21-1377 |
Ejemplares similares
-
Local treatment of synchronous oligometastatic non-small cell lung cancer (NSCLC)—current consensus and future perspectives
por: Almeldin, Doaa Said, et al.
Publicado: (2020) -
Synchronous Oligometastatic Non-small Cell Lung Cancer Managed With Curative-Intent Chemoradiation Therapy: Long-term Outcomes From a Single Institution
por: Yegya-Raman, Nikhil, et al.
Publicado: (2019) -
Combining radiation therapy and immunotherapy for lung cancers: a narrative review
por: Modi, Chirag, et al.
Publicado: (2021) -
Peutz-Jeghers syndrome with germline mutation of STK11
por: Chae, Hyun-Dong, et al.
Publicado: (2014) -
Mutations in STK11 gene in Czech Peutz-Jeghers patients
por: Vasovčák, Peter, et al.
Publicado: (2009)